The abstract is read at the publisher; the summary is JClub's.
High-throughput base editor tiling in lung cancer cells identifies SHP2 gain-of-function mutations linked to resistance against migoprotafib and TNO155, including variants enriched in tumors.
- Why it matters: SHP2 is a promising cancer target, but how SHP2 mutations affect response to SHP2 inhibitors is unclear, limiting prediction of intrinsic resistance in patients.
- What they did: The study used high-throughput mutagenic base editor screens in lung cancer cells, then cross-referenced screen-enriched mutations with genomic profiling from predominantly advanced, SHP2 inhibitor-naive tumors.
- The result: Many resistance mutations overlap between inhibitors, with some showing higher resistance to TNO155 than migoprotafib; validated mutations and structural analyses map variants that may reduce inhibitor sensitivity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.